CFTR and cystic fibrosis: With additional CFTR modulator approvals (4–6) culminating in the 2019 approval of a triple-combination therapy, elexacaftor, tezacaftor, and ivacaftor (trade name Trikafta) (7), as many as 90% of individuals with CF are now eligible for an FDA-approved modulator therapy.